UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
☒ QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended: September 30,
2024
or
☐ TRANSITION REPORT PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from __________ to __________
Commission File Number: 000-52759
BESPOKE EXTRACTS, INC.
(Exact name of registrant as specified in its charter)
Nevada | | 20-4743354 |
(State or other jurisdiction
of incorporation) | | (IRS Employer
Identification No.) |
12001 E. 33rd Street Unit O
Aurora, CO 80010
(Address of principal executive offices)
720-949-1143
(Registrant’s telephone number, including
area code)
(Former name, former address and former fiscal
year, if changed since last report)
Securities registered pursuant to Section 12(b)
of the Act: None.
Indicate by check mark whether the registrant
(1) has filed all reports required to be filed by section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months,
and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant
has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405
of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.
See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,”
and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☐ | Accelerated filer | ☐ |
Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
| Emerging growth company | ☒ |
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As of November 8, 2024, there were
11,123,552 shares outstanding of the registrant’s common stock, par value $0.001.
TABLE OF CONTENTS
PART I
Item 1. Financial Statements.
Bespoke Extracts, Inc.
Consolidated Balance Sheets
| |
September 30, | | |
December 31, | |
| |
2024 | | |
2023 | |
| |
(Unaudited) | | |
| |
Assets | |
| | |
| |
Current assets | |
| | |
| |
Cash | |
$ | 21,445 | | |
$ | 6,607 | |
Accounts receivable | |
| 46,083 | | |
| 45,226 | |
Prepaid stock awards | |
| - | | |
| 9,206 | |
Prepaid expense | |
| 12,295 | | |
| 5,000 | |
Inventory, net | |
| 44,227 | | |
| 15,800 | |
Total current assets | |
| 124,050 | | |
| 81,839 | |
| |
| | | |
| | |
Furniture and equipment, net | |
| 33,959 | | |
| 40,979 | |
License | |
| 10,000 | | |
| 10,000 | |
Right of Use Asset | |
| 158,006 | | |
| 209,542 | |
Deposits | |
| 12,000 | | |
| 12,000 | |
Total assets | |
$ | 338,015 | | |
$ | 354,360 | |
| |
| | | |
| | |
Liabilities and Stockholders’ Equity | |
| | | |
| | |
Current liabilities | |
| | | |
| | |
Accounts payable and accrued liabilities | |
$ | 1,446,989 | | |
$ | 961,255 | |
Note payable | |
| 25,000 | | |
| - | |
Notes payable -- secured (Net of discount of $14,606) | |
| 120,394 | | |
| - | |
Advances-related party | |
| 61,872 | | |
| 53,372 | |
Operating lease liability | |
| 73,523 | | |
| 64,330 | |
Total current liabilities | |
| 1,727,778 | | |
| 1,078,957 | |
| |
| | | |
| | |
Note payable - related party | |
| 849,500 | | |
| 849,500 | |
Long-Term Operating Lease Liability | |
| 90,138 | | |
| 150,460 | |
Total liabilities | |
| 2,667,416 | | |
| 2,078,917 | |
| |
| | | |
| | |
Commitments and contingencies (Note 10) | |
| | | |
| | |
| |
| | | |
| | |
Stockholders’ Deficit | |
| | | |
| | |
Preferred stock, par value $0.001, 50,000,000 shares authorized, 1 share issued and outstanding as of September 30, 2024 and December 31,2023, respectively | |
| - | | |
| - | |
Series C Convertible Preferred Stock, $0.001 par value, 1 share designated; 1 share issued and outstanding as of September 30, 2024 and December 31, 2023, respectively, stated value $24,000. | |
| - | | |
| - | |
Common stock, $0.001 par value: 3,000,000,000 authorized; 11,123,220 and 9,946,067 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively | |
| 11,121 | | |
| 10,166 | |
Common stock to issue 6,478 shares | |
| - | | |
| - | |
Additional paid-in capital | |
| 23,876,745 | | |
| 23,631,918 | |
Accumulated deficit | |
| (26,217,267 | ) | |
| (25,366,641 | ) |
Total stockholders’ deficit | |
| (2,329,401 | ) | |
| (1,724,557 | ) |
Total liabilities and stockholders’ deficit | |
$ | 338,015 | | |
$ | 354,360 | |
The accompanying notes are an integral part of these consolidated financial statements.
Bespoke Extracts, Inc.
Consolidated Statements of Operations
(Unaudited)
| |
For the three months ended September 30, | | |
For the nine months ended September 30, | |
| |
2024 | | |
2023 | | |
2024 | | |
2023 | |
| |
| | |
| | |
| | |
| |
Sales | |
$ | 277,471 | | |
$ | 244,408 | | |
$ | 816,062 | | |
$ | 521,671 | |
Cost of products sold | |
| 162,476 | | |
| 146,000 | | |
| 492,369 | | |
| 341,878 | |
Gross Profit | |
| 114,995 | | |
| 98,408 | | |
| 323,693 | | |
| 179,793 | |
| |
| | | |
| | | |
| | | |
| | |
Operating expenses: | |
| | | |
| | | |
| | | |
| | |
Selling, general and administrative expenses | |
| 290,723 | | |
| 347,717 | | |
| 964,467 | | |
| 1,179,598 | |
Professional fees | |
| 16,070 | | |
| 46,883 | | |
| 104,070 | | |
| 171,259 | |
Consulting | |
| 70,670 | | |
| - | | |
| 70,670 | | |
| 36,000 | |
Total operating expenses | |
| 377,463 | | |
| 394,600 | | |
| 1,139,207 | | |
| 1,386,857 | |
| |
| | | |
| | | |
| | | |
| | |
Loss from operations | |
| (262,468 | ) | |
| (296,192 | ) | |
| (815,514 | ) | |
| (1,207,064 | ) |
| |
| | | |
| | | |
| | | |
| | |
Other income / (expenses) | |
| | | |
| | | |
| | | |
| | |
Interest expense | |
| (13,145 | ) | |
| (5,337 | ) | |
| (35,112 | ) | |
| (6,692 | ) |
Total other (expense) / income | |
| (13,145 | ) | |
| (5,337 | ) | |
| (35,112 | ) | |
| (6,692 | ) |
| |
| | | |
| | | |
| | | |
| | |
Loss before income tax | |
| (275,613 | ) | |
| (301,529 | ) | |
| (850,626 | ) | |
| (1,213,756 | ) |
Provision for income tax | |
| - | | |
| - | | |
| - | | |
| - | |
Net Loss | |
$ | (275,613 | ) | |
$ | (301,529 | ) | |
$ | (850,626 | ) | |
$ | (1,213,756 | ) |
| |
| | | |
| | | |
| | | |
| | |
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING | |
| | | |
| | | |
| | | |
| | |
Basic and Diluted | |
| 10,635,068 | | |
| 10,168,220 | | |
| 10,324,972 | | |
| 10,165,778 | |
| |
| | | |
| | | |
| | | |
| | |
NET LOSS PER COMMON SHARE OUTSTANDING | |
| | | |
| | | |
| | | |
| | |
Basic and Diluted | |
$ | (0.03 | ) | |
$ | (0.03 | ) | |
$ | (0.08 | ) | |
$ | (0.12 | ) |
The accompanying notes are an integral part of
these consolidated financial statements.
Bespoke Extracts, Inc.
Consolidated Statement of Stockholders Deficit
For The three and nine months ended September
30, 2024 and September 30, 2023
(Unaudited)
| |
Preferred | | |
Preferred | | |
Common | | |
Common | | |
Additional | | |
| | |
| |
| |
Shares | | |
Par | | |
Shares | | |
Par | | |
Paid-in | | |
Accumulated | | |
| |
| |
Outstanding | | |
Amount | | |
Outstanding | | |
Amount | | |
Capital | | |
Deficit | | |
Total | |
| |
| | |
| | |
| | |
| | |
| | |
| | |
| |
Balance June 30, 2023 | |
| 1 | | |
$ | - | | |
| 10,168,220 | | |
$ | 10,166 | | |
$ | 23,436,312 | | |
$ | (24,796,025 | ) | |
$ | (1,349,547 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Stock option expense | |
| - | | |
| - | | |
| - | | |
| | | |
| 97,303 | | |
| - | | |
| 97,303 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Net loss for the three months ended September 30, 2023 | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (301,529 | ) | |
| (301,529 | ) |
Balance September 30, 2023 | |
| 1 | | |
$ | - | | |
| 10,168,220 | | |
$ | 10,166 | | |
$ | 23,533,615 | | |
$ | (25,097,554 | ) | |
$ | (1,553,773 | ) |
| |
Series C | | |
| | |
| | |
| | |
| | |
| |
| |
Preferred | | |
Preferred | | |
Common | | |
Common | | |
Additional | | |
| | |
| |
| |
Shares | | |
Par | | |
Shares | | |
Par | | |
Paid-in | | |
Accumulated | | |
| |
| |
Outstanding | | |
Amount | | |
Outstanding | | |
Amount | | |
Capital | | |
Deficit | | |
Total | |
| |
| | |
| | |
| | |
| | |
| | |
| | |
| |
Balance June 30, 2024 | |
| 1 | | |
$ | - | | |
| 10,168,220 | | |
$ | 10,166 | | |
$ | 23,759,351 | | |
$ | (25,941,654 | ) | |
$ | (2,172,137 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Stock option expense | |
| - | | |
| - | | |
| - | | |
| - | | |
| 47,679 | | |
| - | | |
| 47,679 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Common stock issued for services | |
| - | | |
| - | | |
| 955,000 | | |
| 955 | | |
| 69,715 | | |
| - | | |
| 70,670 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Net loss for the three months ended September 30, 2024 | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (275,613 | ) | |
| (275,613 | ) |
Balance September 30, 2024 | |
| 1 | | |
$ | - | | |
| 11,123,220 | | |
$ | 11,121 | | |
$ | 23,876,745 | | |
$ | (26,217,267 | ) | |
$ | (2,329,401 | ) |
| |
Preferred | | |
Preferred | | |
Common | | |
Common | | |
Additional | | |
| | |
| |
| |
Shares | | |
Par | | |
Shares | | |
Par | | |
Paid-in | | |
Accumulated | | |
| |
| |
Outstanding | | |
Amount | | |
Outstanding | | |
Amount | | |
Capital | | |
Deficit | | |
Total | |
| |
| | |
| | |
| | |
| | |
| | |
| | |
| |
Balance December 31, 2022 | |
| 1 | | |
$ | - | | |
| 9,945,997 | | |
$ | 9,944 | | |
$ | 23,201,758 | | |
$ | (23,883,798 | ) | |
$ | (672,096 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Purchase Wonderleaf | |
| - | | |
| - | | |
| 222,223 | | |
| 222 | | |
| 49,778 | | |
| - | | |
| 50,000 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Stock option expense | |
| - | | |
| - | | |
| - | | |
| | | |
| 282,079 | | |
| - | | |
| 282,079 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Net loss for the nine months ended September 30, 2023 | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (1,213,756 | ) | |
| (1,213,756 | ) |
Balance September 30, 2023 | |
| 1 | | |
$ | - | | |
| 10,168,220 | | |
$ | 10,166 | | |
$ | 23,533,615 | | |
$ | (25,097,554 | ) | |
$ | (1,553,773 | ) |
| |
Series C | | |
| | |
| | |
| | |
| | |
| |
| |
Preferred | | |
Preferred | | |
Common | | |
Common | | |
Additional | | |
| | |
| |
| |
Shares | | |
Par | | |
Shares | | |
Par | | |
Paid-in | | |
Accumulated | | |
| |
| |
Outstanding | | |
Amount | | |
Outstanding | | |
Amount | | |
Capital | | |
Deficit | | |
Total | |
| |
| | |
| | |
| | |
| | |
| | |
| | |
| |
Balance December 31, 2023 | |
| 1 | | |
$ | - | | |
| 10,168,220 | | |
$ | 10,166 | | |
$ | 23,631,918 | | |
$ | (25,366,641 | ) | |
$ | (1,724,557 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Warrants issued with financing | |
| - | | |
| - | | |
| - | | |
| - | | |
| 20,231 | | |
| - | | |
| 20,231 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Stock option expense | |
| - | | |
| - | | |
| - | | |
| - | | |
| 154,881 | | |
| - | | |
| 154,881 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Common stock issued for services | |
| - | | |
| - | | |
| 955,000 | | |
| 955 | | |
| 69,715 | | |
| - | | |
| 70,670 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Net loss for the nine months ended September 30, 2024 | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (850,626 | ) | |
| (850,626 | ) |
Balance September 30, 2024 | |
| 1 | | |
$ | - | | |
| 11,123,220 | | |
$ | 11,121 | | |
$ | 23,876,745 | | |
$ | (26,217,267 | ) | |
$ | (2,329,401 | ) |
The accompanying notes are an integral part of
these consolidated financial statements.
Bespoke Extracts, Inc.
Consolidated Statements of Cash Flows
(Unaudited)
| |
For the nine months ended
September 30, | |
| |
2024 | | |
2023 | |
Cash flows from operating activities | |
| | |
| |
Net Loss | |
$ | (850,626 | ) | |
$ | (1,213,756 | ) |
Adjustments to reconcile net loss to net cash used in operating activities | |
| | | |
| | |
Inventory reserve | |
| - | | |
| 40,393 | |
Depreciation | |
| 7,020 | | |
| 7,183 | |
Amortization of right of use asset, net | |
| 51,536 | | |
| 49,531 | |
Amortization expense for prepaid expenses for consulting shares | |
| 9,206 | | |
| 65,351 | |
Amortization of debt discount | |
| 5,625 | | |
| - | |
Stock based compensation and stock option expense | |
| 154,881 | | |
| 282,079 | |
Stock issued for services | |
| 70,670 | | |
| | |
Changes in operating assets and liabilities: | |
| | | |
| | |
Accounts receivable | |
| (857 | ) | |
| (45,950 | ) |
Prepaid expenses | |
| (7,295 | ) | |
| (3,509 | ) |
Inventory | |
| (28,427 | ) | |
| (65,950 | ) |
Accounts payable and accrued liabilities | |
| 485,734 | | |
| 535,200 | |
Deferred revenue | |
| - | | |
| 2,936 | |
Operating lease liability, net | |
| (51,129 | ) | |
| (48,938 | ) |
Net Cash (used in) operating activities | |
| (153,662 | ) | |
| (395,430 | ) |
| |
| | | |
| | |
Cash flow from financing activities | |
| | | |
| | |
Payment of inventory earnout | |
| | | |
| (90,000 | ) |
Proceeds from issuance of note payable - related party | |
| - | | |
| 434,000 | |
Proceeds from advances - related party | |
| 8,500 | | |
| 26,997 | |
Proceeds from note payable | |
| 25,000 | | |
| | |
Proceeds from secured notes payable | |
| 135,000 | | |
| - | |
Net cash provided by financing activities | |
| 168,500 | | |
| 370,997 | |
| |
| | | |
| | |
Net increase / (decrease) in cash | |
| 14,838 | | |
| (24,433 | ) |
Cash at beginning of period | |
| 6,607 | | |
| 24,433 | |
Cash at end of period | |
$ | 21,445 | | |
$ | - | |
| |
| | | |
| | |
Supplemental disclosure of cash flow information | |
| | | |
| | |
Cash paid for interest | |
$ | - | | |
$ | - | |
Cash paid for income taxes | |
$ | - | | |
$ | - | |
| |
| | | |
| | |
Noncash investing and financing activities: | |
| | | |
| | |
Stock issued to WonderLeaf for fixed assets and license | |
$ | - | | |
$ | 50,000 | |
The accompanying notes are an integral part of
these consolidated financial statements.
BESPOKE EXTRACTS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2024
(Unaudited)
1. NATURE OF OPERATIONS, SIGNIFICANT ACCOUNTING POLICIES AND GOING
CONCERN
Nature of Business Operations
Bespoke Extracts, Inc. (the “Company”)
is a Nevada corporation focused on operating in the regulated cannabis markets in the United States. Through Bespoke Extracts Colorado,
LLC (“Bespoke Colorado”), we operate a marijuana infused products production facility in Aurora, Colorado.
On December 2, 2021, Bespoke Colorado, a newly
formed wholly-owned subsidiary of the Company entered into an asset purchase agreement with WonderLeaf, LLC (“WonderLeaf”),
and on December 7, 2021, Bespoke Colorado and WonderLeaf entered into an amendment to such asset purchase agreement (as amended, the
“WonderLeaf Purchase Agreement”). On January 3, 2023, the Company completed the acquisition of the WonderLeaf assets and
the change of control was approved by the Colorado Marijuana Enforcement Division for 222,223 shares of common stock valued at $50,000,
or $0.225 per share. At the time of acquisition WonderLeaf had no operations, no employees and was not considered a business.
Principles of Consolidation
The accompanying condensed consolidated unaudited
financial statements include the accounts of Bespoke Extracts, Inc., and its wholly owned subsidiary Bespoke Extracts Colorado, LLC.
All inter-company balances have been eliminated.
Going Concern
The accompanying consolidated financial statements
have been prepared assuming a continuation of the Company as a going concern. The Company had negative cash flows from operations of $153,662
for the nine months ended September 30, 2024, and a working capital deficit of $1,603,728 and accumulated deficit of $26,217,267, as of
September 30, 2024. This raises substantial doubt about our ability to continue as a going concern for a period of one year from
the date of these financial statements.
The Company’s ability to continue as a
going concern is dependent upon the Company generating profitable operations in the future and/or obtaining the necessary financing to
meet its obligations and repay its liabilities arising from normal business operations when they come due. There is no assurance that
this series of events will be satisfactorily completed.
Further, if we issue additional equity or debt
securities, stockholders may experience additional dilution or the new equity securities may have rights, preferences or privileges senior
to those of existing holders of our common stock. If additional financing is not available or is not available on acceptable terms, we
will have to curtail or cease our operations. The financial statements do not include any adjustments relating to the recoverability
and classification of recorded assets, or the amounts of and classification of liabilities that might be necessary in the event the Company
cannot continue in existence. These financial statements do not include any adjustments that might arise from this uncertainty.
Use of Estimates
The preparation of consolidated financial statements
in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions
that affect the amounts reported in the accompanying consolidated financial statements and accompanying notes. Significant estimates
include the assumption used in the valuation of equity-based transactions, valuation of intangible assets, allowance for provision for
credit losses and inventory valuation and reserves. Actual results could differ from those estimates.
Cash and Cash Equivalents
Cash and cash equivalents include all highly
liquid investments with original maturities of three months or less at the time of purchase. At September 30, 2024 and December 31, 2023,
the Company did not have any cash equivalents. The Company did not have any cash in excess of FDIC limits of $250,000 at any single bank.
Fair Value of Financial Instruments
The carrying amounts of cash, accounts receivable,
inventory, fixed assets, licenses, and other assets, accounts payable, accrued liabilities, and notes payable approximate their fair
values as of September 30, 2024 and December 31, 2023, respectively, because of their short-term natures and the Company’s borrowing
rate of interest.
Accounts Receivable
Accounts receivable are recorded at fair value
on the date revenue is recognized. The Company provides allowances for provision for credit losses for estimated losses resulting from
the inability of its customers to repay their obligation. If the financial condition of the Company’s customers were to deteriorate,
resulting in an impairment of their ability to repay, additional allowances may be required. The Company provides for potential uncollectible
accounts receivable based on specific customer identification and historical collection experience adjusted for existing market conditions.
If market conditions decline, actual collection experience may not meet expectations and may result in decreased cash flows and increased
provision for credit losses.
The policy for determining past due status is based on the contractual payment terms of each customer, which are generally net 14 or net
30 days. Once collection efforts by the Company are exhausted, the determination for charging off uncollectible receivables is made. At
September 30, 2024 and December 31, 2023, the Company recorded a provision for credit losses of $0 and $0, respectively.
Inventory, net
Inventories are stated at the lower of cost or
net realizable value. Cost is determined by the first-in, first-out basis and net realizable value. Net realizable value is defined
as sales price less cost of completion, disposition and transportation and a normal profit margin. As of September 30, 2024 and December
31, 2023, inventory amounted to $44,227, and $15,800 net of reserves, respectively, which consisted of raw materials of $44,227 and
$15,800.
Property and equipment
Property and equipment is recorded at cost and
capitalized from the initial date of service. Expenditures for major additions and improvements are capitalized and minor replacements,
maintenance, and repairs are charged to expense as incurred. When property and equipment is retired or otherwise disposed of, the cost
and accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations for
the respective period. Depreciation is provided over the estimated useful lives of the related assets using the straight-line method
for financial statement purposes. The Company uses other depreciation methods (generally accelerated) for tax purposes where appropriate.
The estimated useful lives for significant property and equipment categories are as follows:
Schedule of Estimated useful Lives of Property
and Equipment
Furniture and Equipment | | 5 years |
License
License represents the Colorado license for distributing cannabis.
Revenue Recognition
We account for revenue in accordance with the
Financial Accounting Standards Board (“FASB”) Accounting Standard Codification Topic 606, “Revenue from Contracts
with Customers”. Revenue is measured based on the amount of consideration that we expect to receive, reduced by discounts and estimates
for credits and returns (calculated based upon previous experience and management’s evaluation). Outbound shipping charged to customers
is recognized at the time the related merchandise revenues are recognized and are included in net revenues. Inbound and outbound shipping
and delivery costs are included in cost of revenues.
Our products are sold directly to licensed marijuana
dispensaries in Colorado. Revenue is recognized when control of the merchandise is transferred to the customer, which generally occurs
upon shipment. Payment is typically due on the date of shipment or within 14 to 30 days.
As of September 30, 2024 two customers amounted
to 16.0% and 10.0% of the accounts receivable.
As of December 31, 2023, two customers amounted
to 19.4% and 14.9% of accounts receivable.
Stock Based Compensation
Stock options and warrants issued to consultants
and other non-employees as compensation for services provided to the Company are accounted for based on the fair value of the services
provided or the estimated fair market value of the option or warrant, whichever is more reliably measurable, and in accordance with FASB
ASC 718, Compensation-Stock Compensation, including related amendments and interpretations.
Net Income / (Loss) per Share
Basic income / (loss) per share amounts are computed
based on net income / (loss) divided by the weighted average number of common shares outstanding. Diluted earnings per share reflect
the potential dilution that could occur if potentially dilutive securities were exercised or converted to common stock. The dilutive
effect of options and warrants and their equivalent is computed by application of the treasury stock method and the effect of convertible
securities by the “if converted” method. The effect of 164,876 warrants and 1,565,341 options is anti-dilutive
for the Nine months ended September 30, 2024, as they are not in the money.
Recent accounting pronouncements
From time to time, new accounting pronouncements
are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that are adopted by the
Company as of the specified effective date.
The Company did not adopt any new accounting pronouncements in the
reporting period ended September 30, 2024.
Income Taxes
We utilize the asset and liability method of
accounting for income taxes. We recognize deferred tax liabilities or assets for the expected future tax consequences of temporary differences
between the book and tax basis of assets and liabilities. We regularly assess the likelihood that our deferred tax assets will be recovered
from future taxable income. We consider projected future taxable income and ongoing tax planning strategies in assessing the amount of
the valuation allowance necessary to offset our deferred tax assets that will not be recoverable. We have recorded and continue to carry
a full valuation allowance against our gross deferred tax assets that will not reverse against deferred tax liabilities within the scheduled
reversal period. If we determine in the future that it is more likely than not that we will realize all or a portion of our deferred
tax assets, we will adjust our valuation allowance in the period we make the determination. We expect to provide a full valuation allowance
on our future tax benefits until we can sustain a level of profitability that demonstrates our ability to realize these assets.
2. ASSET PURCHASE AGREEMENT
On January 3, 2023, the Company completed the
acquisition of the WonderLeaf assets for 222,223 shares of common stock valued at $50,000, or $0.225 per share. At the time of acquisition
WonderLeaf had no operations or no employees and was not considered a business.
Pursuant to ASU 2017-01 and ASC 805, the Company
analyzed the business of WonderLeaf to determine if the Company acquired a business or acquired assets. Based on this analysis, the Company
determined that it acquired assets. No goodwill was recorded since the purchase was accounted for as an asset purchase. In accordance
with ASC 805, the fair value of the assets acquired is based on either the fair value of the consideration given or the fair value of
the assets acquired, whichever is more clearly evident, and thus, more reliably measurable. The Company used the market price of the
222,223 common shares issued of $50,000 as the fair value of the assets acquired since this value was more clearly evident, and thus,
more reliably measurable than the fair value of the license and fixed assets acquired.
Company management determined if the Company
acquired a business or acquired assets. The FASB issued new guidance (ASU 2017-01) that changed the definition of a business to assist
entities with evaluating when a set of transferred assets and activities is a business. The guidance requires an entity to evaluate if
substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or a group of similar
identifiable assets; if so, the set of transferred assets and activities is not a business. The guidance also requires a business to
include at least one substantive process and narrows the definition of outputs by more closely aligning it with how outputs are described
in ASC 606. Under the new guidance, an entity first determines whether substantially all of the fair value of the gross assets acquired
is concentrated in a single identifiable asset or a group of similar identifiable assets. If this threshold is met, the set is not a
business. If it’s not met, the entity then evaluates whether the set meets the requirement that a business include, at a minimum,
an input and a substantive process that together significantly contribute to the ability to create outputs. Under the ASU, a set is not
a business when substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or a
group of similar identifiable assets.
Pursuant to 805-10-55-83, the Company first considered
the guidance in paragraphs 805-10-55-5A through 55-5C. The identifiable assets that could be recognized in the purchase only included
the license and fixed assets. Accordingly, the transaction was not considered a business.
The monetary value of the 222,223 shares is deemed
by the Company to be $50,000 in accordance with Accounting Standards Codification (“ASC”) 805-50-30 “Business Combinations”,
the Company determined that if the consideration paid is not in the form of cash, the measurement may be based on either (i) the cost
which is measured based on the fair value of the consideration given or (ii) the fair value of the assets (or net assets) acquired, whichever
is more clearly evident and thus more reliably measurable. No goodwill should be recorded since the WPA was accounting for as an asset
purchase. The Company determined that the fair value of the common shares issued was a better indicator which is more reliably measurable.
The Company assigned a value of $10,000 to the
licenses and $40,000 to the fixed assets acquired.
3. FURNITURE AND EQUIPMENT, NET
Machinery and equipment consisted of the following
at:
Schedule of Machinery and Equipment
|
|
September 30,
2024 |
|
|
December 31,
2023 |
|
Furniture and equipment |
|
$ |
2,745 |
|
|
$ |
2,745 |
|
Machinery and Equipment |
|
|
47,202 |
|
|
|
47,202 |
|
Fixed assets, total |
|
|
49,947 |
|
|
|
49,947 |
|
Total: accumulated depreciation |
|
|
(15,988 |
) |
|
|
(8,968 |
) |
Fixed assets, net |
|
$ |
33,959 |
|
|
$ |
40,979 |
|
Depreciation expense for the three and nine months
ended September 30, 2024 and 2023 were $2,618, $7,020, $2,617 and $7,183 respectively.
4. NOTE PAYABLE – RELATED PARTY
During the year ended December 31, 2023, Infinity
Management, LLC an affiliate of Michael Feinsod, the Company’s chief executive officer, loaned the Company an additional $469,954.
On September 5, 2023 $849,500 of notes payable were converted into a 5.0% interest bearing note due June 30, 2025 (the
“Infinity Note”). In addition, repayment of the Infinity Note will be due out of the proceeds of a new debt or equity capital
raise with net proceeds of more than $2,000,000. As of September 30, 2024 and December 31, 2023 the amount owed Infinity Management,
LLC is $911,372 and $902,872, respectively.
During the year ended December 31, 2023 the Company
received additional advances from Infinity Management, LLC of $53,372. During the nine months ended September 30, 2024 the Company received
additional advances from Infinity Management, LLC of $8,500.
5. NOTE PAYABLE
On September 5, 2024, the Company entered into
and closed on an unsecured note payable in the amount of $25,000. The note is non-interest bearing and payable upon demand. As of September
30, 2024 the amount owed on the loan is $25,000.
6. NOTE PAYABLE – SECURED
On February 16, 2024, the Company entered into
and closed securities purchase agreements with investors pursuant to which the Company issued and sold to the investors an aggregate of
$100,000 in 15% Senior Secured Notes due February 15, 2025 (the “Notes”), and warrants to purchase an aggregate of 100,000
shares of common stock, for an aggregate purchase price of $100,000. The Notes are senior in terms of priority and liquidation to all
other existing debt obligations of the Company. The warrants have a term of two years and an exercise price of $0.11. The warrants were
valued at $15,636 using a Black-Scholes pricing model with the following assumptions: dividend yield of 0%, annual volatility of
583%, risk free interest rate of 4.64%, an expected life of 1 years. The Company utilized the Relative Fair Value to allocate the value
of the warrants and recorded it as debt discount.
On May 20, 2024 the Company entered into and closed
securities purchase agreements with investors pursuant to which the Company issued and sold to the investors an aggregate of $10,000 in 15%
Senior Secured Notes due May 20, 2025 and warrants to purchase an aggregate of 10,000 shares of common stock, for an aggregate
purchase price of $10,000. The Notes are senior in terms of priority and liquidation to all other existing debt obligations of the Company.
The warrants have a term of two years and an exercise price of $0.11. The warrants were valued at $15,636 using a Black-Scholes
pricing model with the following assumptions: dividend yield of 0%, annual volatility of 608%, risk free interest rate of 5.42%, an expected
life of 1 years. The Company utilized the Relative Fair Value to allocate the value of the warrants and recorded it as debt discount.
On June 6, 2024 the Company entered into and closed
securities purchase agreements with investors pursuant to which the Company issued and sold to the investors an aggregate of $25,000 in
15% Senior Secured Notes due June 6, 2025 and warrants to purchase an aggregate of 25,000 shares of common stock, for an aggregate purchase
price of $25,000. The Notes are senior in terms of priority and liquidation to all other existing debt obligations of the Company. The
warrants have a term of two years and an exercise price of $0.11. The warrants were valued at $15,636 using a Black-Scholes pricing
model with the following assumptions: dividend yield of 0%, annual volatility of 614%, risk free interest rate of 4.72%, an expected life
of 1 years. The Company utilized the Relative Fair Value to allocate the value of the warrants and recorded it as debt discount.
| |
September 30, 2024 | |
Note amount | |
$ | 135,000 | |
Debt discount | |
| (20,231 | ) |
Amortization of debt discount | |
| 5,625 | |
Notes payable, net | |
$ | 120,394 | |
7. LEASES
In connection with the WonderLeaf Purchase Agreement,
Bespoke Colorado entered into a lease agreement (the “Lease”) with WL Holdings, Ltd. (“WL Holdings”) in December
2021. Pursuant to the Lease, Bespoke Colorado will lease from WL Holdings certain commercial space in Aurora, Colorado, where WonderLeaf’s
business has been located, commencing upon signing of the Lease and Wonderleaf Purchase Agreement, for a term of five years, which Bespoke
Colorado will have an option to renew for an additional five years. Monthly rent under the Lease will start at $6,000. The Lease grants
the Company an option to purchase the property for $600,000. The Company has not decided whether it will exercise either option.
Supplemental balance sheet information related to leases was as follows:
| |
| |
September 30, | |
Operating Leases | |
Classification | |
2024 | |
Right-of-use assets | |
Right of use assets | |
$ | 158,006 | |
| |
| |
| | |
Current lease liabilities | |
Current operating lease liabilities | |
| 73,523 | |
Non-current lease liabilities | |
Long-term operating lease liabilities | |
| 90,138 | |
Total lease liabilities | |
| |
$ | 163,661 | |
Lease term and discount rate were as follows:
| | September 30, | |
| | 2024 | |
Weighted average remaining lease term (years) | | | 3.19 | |
Weighted average discount rate | | | 4 | % |
The component of lease costs was as follows:
| |
September 30, | |
| |
2024 | |
Operating lease cost | |
$ | 57,294 | |
Variable lease cost (1) | |
| 3,150 | |
Total lease costs | |
$ | 60,444 | |
|
|
September 30, |
|
|
|
2024 |
|
Cash paid for operating lease liabilities |
|
$ |
- |
|
|
|
|
|
|
Maturities of lease liabilities were as follows as of September 30,
2024:
| |
Operating | |
| |
Leases | |
2024 | |
$ | 19,215 | |
2025 | |
| 79,380 | |
2026 | |
| 72,765 | |
Total undiscounted lease payments | |
| 171,360 | |
Less: Present value discount | |
| (7,699 | ) |
Total Present value of lease liabilities | |
$ | 163,661 | |
8. EQUITY
Common Stock and Preferred Stock
On December 5, 2022 the Company approved an amendment
to its articles of incorporation to effect a 45-to-1 reverse split of our common stock effective January 13, 2023. All prior amounts
equity amounts have been presented to reflect this reverse split.
As of September 30, 2024 and 2023, the Company’s
authorized capital stock consists of 3,000,000,000 shares of common stock, par value $0.001, and 50,000,000 shares
of preferred stock, par value $0.001. 1,000 shares of preferred stock are designated as Series A Convertible Preferred Stock.
No shares of Series A Preferred Stock are issued and outstanding as of September 30, 2024 and 2023, respectively. The Company’s
Certificate of Designation of Series B Preferred Stock was withdrawn by the Company on September 30, 2020. 1 share of preferred
stock is designated Series C Preferred Stock and is issued and outstanding as of September 30, 2024 and 2023, respectively. The Series
C Preferred Stock has a stated value of $24,000 and entitles the holder to 51% of the total voting power of the Company’s
stockholders. The Company may, in its sole discretion, redeem the Series C Preferred Stock at any time for a redemption price equal to
the stated value. Upon payment of the redemption price by the Company, the Series C Preferred Stock will revert to the status of authorized
but unissued preferred stock.
On January 3, 2023, the Company completed the
acquisition of the WonderLeaf assets for 222,223 shares of common stock valued at $50,000, or $0.225 per share.
On December 14, 2021, the board of directors
of the Company adopted the Company’s 2021 Equity Incentive Plan (the “2021 Plan”), pursuant to which up to an aggregate
of 6,666,667 shares of common stock are available for issuance. Awards under the plan may include options (including incentive
stock options and non-qualified stock options), stock appreciation rights, restricted stock, restricted stock units, performance share
awards, or other equity-based awards, each as defined under the 2021 Plan. Options awarded under the 2021 Plan are to have an exercise
price of not less than 100% of the fair market value of the common stock on the grant date and a term of not more than ten
years from the option grant date.
Effective August 1, 2022, the Company issued
an aggregate of 266,667 shares of common stock to employees and consultants for services, including 155,556 shares that
vest immediately, 55,556 shares that vested one year from the grant date, and 55,556 shares that will vest two years
from the grant date. During the year ended December 31, 2022 the Company recorded an expense $1,104,928. For the year ended December
31, 2023 the Company recorded an expense of $70,907, respectively. For the nine months ended September 30, 2024 the Company recorded
and expense of $9,206. As of September 30, 2024 and December 31, 2023 the Company had a prepaid stock award of $0 and $9,206.
In August 2024 the Company issued a total of 955,000
shares of common stock valued at $70,670 ($0.074 per share) to several consultants and employees for services.
Warrants
On February 16, 2024, the Company entered into
and closed securities purchase agreements with investors pursuant to which the Company issued and sold to the investors an aggregate
of $100,000 in 15% Senior Secured Notes due February 15, 2025 (the “Notes”), and warrants to purchase an aggregate of 100,000
shares of common stock, for an aggregate purchase price of $100,000. The Notes are senior in terms of priority and liquidation to all
other existing debt obligations of the Company. The warrants have a term of two years and an exercise price of $0.11.
On May 20, 2024 the Company entered into and closed
securities purchase agreements with investors pursuant to which the Company issued and sold to the investors an aggregate of $10,000 in 15%
Senior Secured Notes due May 20, 2025 and warrants to purchase an aggregate of 10,000 shares of common stock, for an aggregate
purchase price of $10,000. The Notes are senior in terms of priority and liquidation to all other existing debt obligations of the Company.
The warrants have a term of two years and an exercise price of $0.11
On June 6, 2024 the Company entered into and closed
securities purchase agreements with investors pursuant to which the Company issued and sold to the investors an aggregate of $25,000 in
15% Senior Secured Notes due June 6, 2025 and warrants to purchase an aggregate of 25,000 shares of common stock, for an aggregate purchase
price of $25,000. The Notes are senior in terms of priority and liquidation to all other existing debt obligations of the Company. The
warrants have a term of two years and an exercise price of $0.11.
The following table summarizes the warrant activities
during the nine months ended September 30, 2024:
| | Number of Warrants | | | Weighted- Average Exercise Price Per Share | | | Weighted- Average Remaining Life |
Outstanding at December 31, 2023 | | | 29,876 | | | | 25.24 | | | 1.21 |
Granted | | | 135,000 | | | | 0.15 | | | 1.18 |
Canceled or expired | | | - | | | | - | | | - |
Outstanding at September 30, 2024 | | | 164,876 | | | $ | 0.43 | | | 4.57 years |
Exercisable at September 30, 2024 | | | 164,876 | | | $ | 0.43 | | | 4.57 years |
Intrinsic value at September 30, 2024 | | | | | | $ | - | | | |
Options
On December 14, 2021, the Company entered into
an employment agreement with Hunter Garth, wherein the Company granted to Mr. Garth, pursuant to the Company’s 2021 Equity Incentive
Plan, ten-year options to purchase 333,333 shares of common stock at an exercise price of $2.70 (representing a 120% premium over the
closing price of the common stock on December 13, 2021). One-third of the options will vest on each yearly anniversary of the date of
grant. The options were valued at $450,000 using a Black-Scholes pricing model. During the three and nine months ending September 30,
2024 and 2023 the Company recorded $12,318, $36,953, $30,811 and $92,432 respectively of expenses associated with the vesting
of these stock options. (See notes 11 and 12).
On December 14, 2021, the Company entered into
an employment agreement with Michael Feinsod, wherein the Company granted to Mr. Feinsod, pursuant to the Company’s 2021 Equity
Incentive Plan, ten-year options to purchase 666,667 shares of common stock at an exercise price of $2.70 (representing a 120% premium
over the closing price of the common stock on December 13, 2021). One-third of the options will vest on each yearly anniversary of the
date of grant. The options were valued at $900,000 using a Black-Scholes pricing model During the three and nine months ended September
30, 2024 and 2023 the Company recorded $24,635, $73,905, $61,261 and $184,864, respectively of expenses associated with the vesting
of these stock options. (See notes 11 and 12).
On August 17, 2023, the Company issued to several
employees options to purchase a total of 222,500 shares of common stock at an exercise price of $0.20. The options vest over a period
of 12 months and have a term of 5 years. The options were valued at $44,306 using a Black-Scholes pricing model. During the three and
nine months ended September 30, 2024 the Company recorded $4,626, $26,269 $5,100 and $5,100, respectively of expenses associated with
the vesting of these stock options
On January 8, 2024, the Company issued to an employee
options to purchase a total of 225,000 shares of common stock at an exercise price of $0.20. The options vest 50% on January 15, 2024
and 50% over a period of 12 months and have a term of 10 years. The options were valued at $8,030 using a Black-Scholes pricing model.
During the three and nine months ended September 30, 2024 the Company recorded $1,115 and $7,604, respectively of expenses associated
with the vesting of these stock options
On March 1, 2024, the Company issued to several
employees options to purchase a total of 99,000 shares of common stock at an exercise price of $0.22. The options vest over a period
of 12 months and have a term of 5 years. The options were valued at $44,306 using a Black-Scholes pricing model. During the three and
nine months ended September 30, 2024 the Company recorded $4,986 and $11,543, respectively and of expenses associated with the vesting
of these stock options
The following table summarizes the option activities
during the nine months ended September 30, 2024:
| | Number of Options | | | Weighted- Average Exercise Price Per Share | | | Weighted- Average Remaining Life |
Outstanding at December 31, 2023 | | | 1,246,341 | | | $ | 2.67 | | | 7.94 years |
Granted | | | 324,000 | | | $ | 0.22 | | | 4.67 years |
Canceled or expired | | | (5,000 | ) | | | 0.22 | | | |
Exercised | | | - | | | | - | | | |
Outstanding at September 30, 2024 | | | 1,565,341 | | | $ | 1.81 | | | 6.61 years |
Exercisable at September 30, 2024 | | | 690,508 | | | $ | 2.19 | | | 6.19 years |
Intrinsic value at September 30, 2024 | | | | | | $ | - | | | |
The future expense as of September 30, 2024 is
$46,095.
9. RELATED PARTY TRANSACTIONS
On December 14, 2021, the Company entered into
an employment agreement with Hunter Garth. Pursuant to the employment agreement, Mr. Garth will serve as the Company’s president
and will receive a base monthly salary of $8,000. The Company also granted to Mr. Garth, pursuant to the Company’s 2021 Equity
Incentive Plan, 500,000 shares of restricted common stock, which vested one year from the date of grant, and ten-year
options to purchase 333,333 shares of common stock at an exercise price of $2.70 (representing a 120% premium over the
closing price of the common stock on December 13, 2021). One-third of the options will vest on each yearly anniversary of the date of
grant. In the event that Mr. Garth is terminated without cause or resigns with good reason (each as defined in the employment agreement),
he will be entitled to his monthly base salary for twelve months following such termination.
On December 14, 2021, the Company entered into
an employment agreement with Michael Feinsod, the Company’s chief executive officer and chairman. Pursuant to the employment agreement,
Mr. Feinsod will continue to serve as the Company’s chief executive officer and chairman and will receive a base monthly salary
of $10,000. The Company also granted to Mr. Feinsod, pursuant to the Company’s 2021 Equity Incentive Plan, 1,000,000 shares
of restricted common stock, which vested one year from the date of grant, and ten-year options to purchase 666,667 shares
of common stock at an exercise price of $2.70 (representing a 120% premium over the closing price of the common stock on December
13, 2021). One-third of the options will vest on each yearly anniversary of the date of grant. In the event that Mr. Feinsod is terminated
without cause or resigns with good reason (each as defined in the employment agreement), he will be entitled to his monthly base salary
for twelve months following such termination.
During the year ended December 31, 2023 the Company
received additional advances from Infinity Management, LLC. of $53,372. During the nine months ended September 30, 2024 the Company received
additional advances from Infinity Management, LLC. of $8,500.
On September 5, 2023 $849,500 of notes payable
were converted into a 5% interest bearing note due June 30, 2025. The note contains provisions whereby it is intended to be
subordinate to any senior secured debt the Company may incur while it is outstanding. In addition, repayment of the note will be due in
full out of the proceeds of a new debt or equity capital raise with net proceeds of more than $2,000,000. (See Note 4.)
As of September 30, 2024 Michael Feinsod is owed a
total of $296,772 of accrued salary and accounts payable of $171,553.
10. COMMITMENTS AND CONTINGENCIES
In connection with a stock purchase agreement,
on October 28, 2021, a convertible debenture with an original issue date of December 24, 2019, as amended by Amendment No. 1 thereto,
dated May 28, 2020, Amendment No. 2 thereto, dated August 21, 2020, Amendment No. 3 thereto, dated December 10, 2020, Amendment No. 4
thereto, dated January 15, 2021, Amendment No. 5 thereto, dated April 2, 2021, and Amendment No. 6 thereto, dated August 2, 2021 (as
amended, the “Debenture”) with an original principal amount of approximately $400,000 was terminated, and all amounts
due and payable thereunder forgiven pursuant to a cancellation and satisfaction of debenture agreement entered into between the Company
and the Debenture holder (the “Debt Cancellation Agreement”). In exchange for cancellation of the debt owed under the Debenture,
the Company transferred to the holder certain domain names and agreed to pay the holder, beginning December 1, 2021, and on a monthly
basis through August 31, 2022, 40% of the operating profit generated from sale of the existing CBD inventory of the Company (the
“Inventory Earn Out”), and on August 31, 2022, to make a final payment equal to an amount of $75,000 minus the total of the
monthly payments made under the Inventory Earn Out. The inventory earn-out agreement was amended on November 11, 2022 (see Note 3) such
that the final payment under the inventory earn out was increased to $90,000 (less any payments previously made) and was due February
28, 2023. During the year ended December 31, 2023 the amount was paid.
On December 14, 2021, the Company entered into
an employment agreement with Hunter Garth. Pursuant to the employment agreement, Mr. Garth will serve as the Company’s president
and will receive a base monthly salary of $8,000. The Company also granted to Mr. Garth, pursuant to the Company’s 2021 Equity
Incentive Plan, 500,000 shares of restricted common stock, which vested one year from the date of grant, and ten-year
options to purchase 333,333 shares of common stock at an exercise price of $2.70 (representing a 120% premium over the
closing price of the common stock on December 13, 2021). One-third of the options will vest on each yearly anniversary of the date of
grant. In the event that Mr. Garth is terminated without cause or resigns with good reason (each as defined in the employment agreement),
he will be entitled to his monthly base salary for twelve months following such termination.
On December 14, 2021, the Company entered into
an employment agreement with Michael Feinsod, the Company’s chief executive officer and chairman. Pursuant to the employment agreement,
Mr. Feinsod will continue to serve as the Company’s chief executive officer and chairman and will receive a base monthly salary
of $10,000. The Company also granted to Mr. Feinsod, pursuant to the Company’s 2021 Equity Incentive Plan, 1,000,000 shares
of restricted common stock, which vested one year from the date of grant, and ten-year options to purchase 666,667 shares
of common stock at an exercise price of $0.06 (representing a 120% premium over the closing price of the common stock on December
13, 2021). One-third of the options will vest on each yearly anniversary of the date of grant. In the event that Mr. Feinsod is terminated
without cause or resigns with good reason (each as defined in the employment agreement), he will be entitled to his monthly base salary
for twelve months following such termination.
On August 11, 2022, the Company and Bespoke Colorado
entered into an asset purchase agreement with Osiris, LLC doing business as Best Day Ever (“BDE”) and Michael Gurtman. Pursuant
to the purchase agreement, Bespoke Colorado agreed to purchase from BDE, and BDE agreed to sell to Bespoke Colorado, the assets of BDE,
including certain licenses. The Company also agreed to assume certain leases, all as further set forth in the purchase agreement. As
consideration for the acquisition of the assets, the Company agreed to issue 2,777,778 shares of common stock at the closing
of the transaction. Closing of the purchase agreement was subject to receipt of certain governmental approvals and other customary closing
conditions. The purchase agreement was terminated on November 18, 2022.
11. SUBSEQUENT EVENTS
Subsequent to September 30, 2024, Infinity Management,
LLC, an affiliate of the Company’s chief executive officer, loaned the Company an additional $10,000.
Effective November 11, 2024 the Company and Infinity Management, LLC, agreed to extend the maturity of the Infinity Note until June 30,
2026.
Item 2. Management’s Discussion and Analysis of Financial
Condition and Results of Operations.
We and our representatives
may from time to time make written or oral statements that are “forward-looking,” including statements contained in this
report and other filings with the SEC, reports to our stockholders and news releases. All statements that express expectations, estimates,
forecasts or projections are forward-looking statements. In addition, other written or oral statements which constitute forward-looking
statements may be made by us or on our behalf. Words such as “expect,” “anticipate,” “intend,” “plan,”
“believe,” “seek,” “estimate,” “project,” “forecast,” “may,”
“should,” and variations of such words and similar expressions are intended to identify such forward-looking statements.
These statements are not guarantees of future performance and involve risks, uncertainties and assumptions which are difficult to predict.
Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in or suggested by such forward-looking
statements. We undertake no obligation to update or revise any of the forward-looking statements after the date of this report to conform
forward-looking statements to actual results, except as may be required under applicable law. Important factors on which such statements
are based are assumptions concerning uncertainties, including but not limited to, uncertainties associated with the following:
| ● | Inadequate
capital and barriers to raising the additional capital or to obtaining the financing needed to implement our business plans; |
| ● | Our
failure to earn significant revenues or profits; |
| ● | Volatility,
lack of liquidity or decline of our stock price; |
| ● | Potential
fluctuation in quarterly results; |
| ● | Rapid
and significant changes in markets; and |
| ● | Insufficient
revenues to cover operating costs. |
The following discussion
should be read in conjunction with the financial statements and the notes thereto which are included in this report.
Overview
Through
our wholly-owned subsidiary, Bespoke Extracts Colorado, LLC, we operate a marijuana infused products manufacturing facility in Colorado.
In
November 2021, new management of the Company was appointed and the Company began to focus on other complimentary lines of business to
its CBD offerings. Under our new management team, we plan to expand the Company’s focus to regulated cannabis markets in the United
States.
On
December 2, 2021, Bespoke Extracts Colorado, LLC, a newly formed wholly-owned subsidiary of the Company entered into an asset purchase
agreement with WonderLeaf, and on December 7, 2021, Bespoke Colorado and WonderLeaf entered into an amendment to such asset purchase
agreement (as amended, the “WonderLeaf Purchase Agreement”). Pursuant to the Wonderleaf Purchase Agreement, Bespoke Colorado
agreed to purchase from WonderLeaf, and WonderLeaf agreed to sell to Bespoke Colorado, certain assets of WonderLeaf, including a license
to manufacture marijuana-infused products, existing inventory, and extraction equipment and ancillary items, all as further set forth
in the WonderLeaf Purchase Agreement, for a purchase price of $50,000, to be paid in shares of common stock of the Company. The Company
issued a total of 222,223 shares of common stock ($0.225 per share), the fair market value on the date of issuance.
Results of Operations for the three months
ended September 30, 2024 and September 30, 2023
Sales
Sales
during the three months ended September 30, 2024 were $277,471 compared to $244,408 for the three months ended September 30, 2023. The
increase in sales was a result of increased product sales of pre-rolled joints to licensed dispensaries in Colorado.
Cost of Goods Sold
Cost
of goods sold for the three months ended September 30, 2024 was $162,476 compared to $146,000 for the three months ended September 30,
2023. The increase was a direct result of the increase in sales. The increase in cost of sales was due to increases in the prices of raw
materials, packaging, and labor associated with the production of pre-rolled joints.
Operating Expenses
Selling,
general and administrative expenses for the three months September 30, 2024 and September 30, 2023 were $290,723 and $347,717, respectively.
The decrease was mainly attributable to stock-based compensation of $47,679 for the three months ended September 30, 2024 compared to
$97,303 for the three months ended September 30, 2023 and were partially offset by increase in salaries. Professional fees were $16,070
and $46,883, respectively for the three months ended September 30, 2024 and September 30, 2023. The decrease in expenses was due to decreased
general legal fees. Consulting expense was $70,670 and $0, for the three months ended September 30, 2024 and September 30, 2023, respectively
During the three months ended September 30, 2024 the Company issued common stock to several consultants valued at $70,670.
Net Loss
Our
net loss for the three months ended September 30, 2024 was $275,613, or $0.03 per share, compared to a net loss for the three months
ended September 30, 2023 of $301,529, or $0.03 per share.
Results of Operations for the nine months
ended September 30, 2024 and September 30, 2023
Sales
Sales
during the nine months ended September 30, 2024 were $816,062 compared to $572,671 for the nine months ended September 30, 2023. The
increase in sales was a result of increased product sales of pre-rolled joints to licensed dispensaries in Colorado.
Cost of Goods Sold
Cost
of goods sold for the nine months ended September 30, 2024 was $492,369 compared to $341,878 for the three months ended September 30,
2023. The increase was a direct result of the increase in sales. The increase in cost of sales was due to increases in purchases of raw
materials, packaging, and labor associated with the production of pre-rolled joints.
Operating Expenses
Selling,
general and administrative expenses for the nine months September 30, 2024 and September 30, 2023 were $964,467 and $1,179,598, respectively.
The decrease was mainly attributable to stock-based compensation of $154,811 for the nine months ended September 30, 2024 compared to
$282,079 for the nine months ended September 30, 2023 and were partially offset by increase in salaries. Professional fees were $104,070
and $171,259, respectively for the nine months ended September 30, 2024 and September 30, 2023. The decrease in expenses was due to decreased
general legal fees.. Consulting expense was $70,670 and $36,000, for the nine months ended September 30, 2024 and September 30, 2023,
respectively During the nine months ended September 30, 2024 the Company issued common stock to several consultants valued at $70,670.
Net Loss
Our
net loss for the nine months ended September 30, 2024 was $850,626, or $0.08 per share, compared to a net loss for the nine months ended
September 30, 2023 of $1,213,756, or $0.12 per share.
Liquidity and Capital
Resources
As
of September 30, 2024, we had cash of $21,445. Net cash used in operating activities for the nine months ended September 30, 2024 was
$153,662. Our current liabilities as of September 30, 2024 were $1,727,778 and consisted of accounts payable and accrued liabilities of
$1,446,989, current portion of lease liability of $73,523, note payable of $25,000, secured notes payable of $120,394 and advances payable
related party of $61,872. As of September 30, 2023, we had cash deficit of $2,949. Net cash used in operating activities for the
nine months ended September 30, 2023 was $398,379. Our current liabilities as of September 30, 2023 were $925,281 and consisted of accounts
payable and accrued liabilities of $828,069, and current portion of lease liability of $64,330 and notes payable related party of $26,997.
During the nine months
ended September 30, 2024 the Company borrowed an additional $8,500 from a related party, $25,000 note payable and secured notes payable
of $135,000. During the nine months ended September 30, 2023 the Company borrowed an additional $26,997 from a related party and repaid
$90,000 owed for an inventory earnout in addition the Company borrowed an additional $434,000 in a Note payable from a related party.
The
unaudited condensed consolidated financial statements included in this report have been prepared assuming a continuation of the Company
as a going concern. The Company had negative cash flows from operations for the nine months ended September 30, 2024 and the year ended
December 31, 2023 and had a working capital deficit at September 30, 2024 and December 31, 2023. This raises substantial doubt about
our ability to continue as a going concern.
We
have not generated positive cash flows from operating activities. Our primary source of capital has been from the sale of equity and
convertible debt securities. Our primary use of capital has been for professional fees and selling, general and administrative costs.
We have no committed sources of capital and will need to raise additional capital to continue and expand our operations. Additional capital
may not be available on terms acceptable to us, or at all.
In
addition, the COVID-19 pandemic may negatively affect our operations, including by limiting access to our facilities, customers, management,
and professional advisors, and by causing delays and constraints in manufacturing and shipping of our products. These factors, in turn,
may negatively impact our operations, financial condition and demand for our products, and our ability to raise capital on acceptable
terms, or at all.
Off-Balance Sheet Arrangements
We have no significant off-balance
sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial
condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.
Critical accounting policies and estimates
The preparation of financial
statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amount of assets and
liabilities, the disclosure of contingent assets and liabilities and the reported amounts of revenue and expenses during the reported
periods. The more critical accounting estimates include estimates related to revenue recognition and accounts receivable allowances.
We also have other key accounting policies, which involve the use of estimates, judgments and assumptions that are significant to understanding
our results, which are described below and in Note 1 to our financial statements appearing elsewhere in this report.
Accounts Receivable
Accounts receivable are recorded at fair value on the date revenue is recognized. The Company provides provision for credit losses resulting
from the inability of its customers to repay their obligation. If the financial condition of the Company’s customers were to deteriorate,
resulting in an impairment of their ability to repay, additional allowances may be required. The Company provides for potential uncollectible
accounts receivable based on specific customer identification and historical collection experience adjusted for existing market conditions.
If market conditions decline, actual collection experience may not meet expectations and may result in decreased cash flows and increased
bad debt expense.
Inventory
Inventories are stated at
the lower of cost or net realizable value. Cost is determined by the first-in, first-out basis and net realizable value. Net realizable
value is defined as sales price less cost of completion, disposition and transportation and a normal profit margin.
Income Taxes
We utilize the asset and
liability method of accounting for income taxes. We recognize deferred tax liabilities or assets for the expected future tax consequences
of temporary differences between the book and tax basis of assets and liabilities. We regularly assess the likelihood that our deferred
tax assets will be recovered from future taxable income. We consider projected future taxable income and ongoing tax planning strategies
in assessing the amount of the valuation allowance necessary to offset our deferred tax assets that will not be recoverable. We have
recorded and continue to carry a full valuation allowance against our gross deferred tax assets that will not reverse against deferred
tax liabilities within the scheduled reversal period. If we determine in the future that it is more likely than not that we will realize
all or a portion of our deferred tax assets, we will adjust our valuation allowance in the period we make the determination. We expect
to provide a full valuation allowance on our future tax benefits until we can sustain a level of profitability that demonstrates our
ability to realize these assets.
Stock Based Compensation
Stock options and warrants
issued to consultants and other non-employees as compensation for services provided to the Company are accounted for based on the fair
value of the services provided or the estimated fair market value of the option or warrant, whichever is more reliably measurable, and
in accordance FASB ASC 718, Compensation-Stock Compensation, including related amendments and interpretations.
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
Not required for smaller
reporting companies.
Item 4. Controls and Procedures.
Evaluation of Disclosure Controls and Procedures
Management of the Company
conducted an evaluation of the effectiveness of the Company’s disclosure controls and procedures (as such term is defined in Rule
13a-15(e) and Rule 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of the end of
the period covered by this report. The Company’s disclosure controls and procedures are designed to ensure that information
required to be disclosed by the Company in the reports it files or submits under the Exchange Act is (i) recorded, processed, summarized
and reported, within the time periods specified in the Commission’s rules and forms, and (ii) accumulated and communicated to our
management, including our principal executive officer and principal financial officer, or persons performing similar functions, as appropriate
to allow timely decisions regarding required disclosure.
Based on this evaluation,
our management has concluded that the design and operation of our disclosure controls and procedures are not effective since the following
material weaknesses exist:
| ● | Our
chief executive officer also functions as our principal financial officer. As a result, our officer may not be able to identify
errors and irregularities in the financial statements and reports; |
| ● | We
were unable to maintain full segregation of duties within our financial operations due to our reliance on limited personnel in the finance
function. While this control deficiency did not result in any audit adjustments to our financial statements, it could have resulted
in a material misstatement that might have been prevented or detected by a segregation of duties; and |
| ● | Documentation
of all proper accounting procedures is not yet complete. |
To the extent reasonably
possible given our limited resources, we intend to take measures to cure the aforementioned weaknesses, including, but not limited to,
increasing the capacity of our qualified financial personnel to ensure that accounting policies and procedures are consistent across
the organization and that we have adequate control over financial statement disclosures.
Changes in Internal Control over Financial
Reporting
There were no changes in
our internal control over financial reporting that occurred during the last fiscal quarter that have materially affected, or are reasonably
likely to materially affect, our internal control over financial reporting.
PART II – OTHER INFORMATION
Item 1. Legal Proceedings.
We are not currently a party
to, nor are any of our property currently the subject of, any material legal proceedings.
Item 1A. Risk Factors.
Not required for smaller
reporting companies.
Item 2. Unregistered Sales of Equity Securities
and Use of Proceeds.
None.
Item 3. Defaults Upon Senior Securities.
None.
Item 4. Mine Safety Disclosures.
No disclosure required.
Item 5. Other Information.
None.
Item 6. Exhibits.
| * | Filed
herewith. |
| ** | Furnished
herewith. |
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
|
BESPOKE EXTRACTS, INC. |
|
|
|
Dated: November 13, 2024 |
By: |
/s/ Michael
Feinsod |
|
|
Michael Feinsod
Chief Executive Officer |
|
|
(Principal Executive Officer,
Principal Financial Officer and
Principal Accounting Officer) |
false
--12-31
Q3
0001409197
0001409197
2024-01-01
2024-09-30
0001409197
2024-11-08
0001409197
2024-09-30
0001409197
2023-12-31
0001409197
us-gaap:RelatedPartyMember
2024-09-30
0001409197
us-gaap:RelatedPartyMember
2023-12-31
0001409197
us-gaap:SeriesCPreferredStockMember
2024-09-30
0001409197
us-gaap:SeriesCPreferredStockMember
2023-12-31
0001409197
2024-07-01
2024-09-30
0001409197
2023-07-01
2023-09-30
0001409197
2023-01-01
2023-09-30
0001409197
us-gaap:PreferredStockMember
2023-06-30
0001409197
us-gaap:CommonStockMember
2023-06-30
0001409197
us-gaap:AdditionalPaidInCapitalMember
2023-06-30
0001409197
us-gaap:RetainedEarningsMember
2023-06-30
0001409197
2023-06-30
0001409197
us-gaap:PreferredStockMember
2023-07-01
2023-09-30
0001409197
us-gaap:AdditionalPaidInCapitalMember
2023-07-01
2023-09-30
0001409197
us-gaap:RetainedEarningsMember
2023-07-01
2023-09-30
0001409197
us-gaap:CommonStockMember
2023-07-01
2023-09-30
0001409197
us-gaap:PreferredStockMember
2023-09-30
0001409197
us-gaap:CommonStockMember
2023-09-30
0001409197
us-gaap:AdditionalPaidInCapitalMember
2023-09-30
0001409197
us-gaap:RetainedEarningsMember
2023-09-30
0001409197
2023-09-30
0001409197
us-gaap:PreferredStockMember
2024-06-30
0001409197
us-gaap:CommonStockMember
2024-06-30
0001409197
us-gaap:AdditionalPaidInCapitalMember
2024-06-30
0001409197
us-gaap:RetainedEarningsMember
2024-06-30
0001409197
2024-06-30
0001409197
us-gaap:PreferredStockMember
2024-07-01
2024-09-30
0001409197
us-gaap:CommonStockMember
2024-07-01
2024-09-30
0001409197
us-gaap:AdditionalPaidInCapitalMember
2024-07-01
2024-09-30
0001409197
us-gaap:RetainedEarningsMember
2024-07-01
2024-09-30
0001409197
us-gaap:PreferredStockMember
2024-09-30
0001409197
us-gaap:CommonStockMember
2024-09-30
0001409197
us-gaap:AdditionalPaidInCapitalMember
2024-09-30
0001409197
us-gaap:RetainedEarningsMember
2024-09-30
0001409197
us-gaap:PreferredStockMember
2022-12-31
0001409197
us-gaap:CommonStockMember
2022-12-31
0001409197
us-gaap:AdditionalPaidInCapitalMember
2022-12-31
0001409197
us-gaap:RetainedEarningsMember
2022-12-31
0001409197
2022-12-31
0001409197
us-gaap:PreferredStockMember
2023-01-01
2023-09-30
0001409197
us-gaap:CommonStockMember
2023-01-01
2023-09-30
0001409197
us-gaap:AdditionalPaidInCapitalMember
2023-01-01
2023-09-30
0001409197
us-gaap:RetainedEarningsMember
2023-01-01
2023-09-30
0001409197
us-gaap:PreferredStockMember
2023-12-31
0001409197
us-gaap:CommonStockMember
2023-12-31
0001409197
us-gaap:AdditionalPaidInCapitalMember
2023-12-31
0001409197
us-gaap:RetainedEarningsMember
2023-12-31
0001409197
us-gaap:PreferredStockMember
2024-01-01
2024-09-30
0001409197
us-gaap:CommonStockMember
2024-01-01
2024-09-30
0001409197
us-gaap:AdditionalPaidInCapitalMember
2024-01-01
2024-09-30
0001409197
us-gaap:RetainedEarningsMember
2024-01-01
2024-09-30
0001409197
bspk:WonderLeafLLCMember
2023-01-03
2023-01-03
0001409197
bspk:WonderLeafLLCMember
2023-01-03
0001409197
bspk:WonderLeafLLCMember
2024-01-01
2024-09-30
0001409197
bspk:CustomerOneMember
us-gaap:AccountsReceivableMember
us-gaap:CustomerConcentrationRiskMember
2024-01-01
2024-09-30
0001409197
bspk:CustomerTwoMember
us-gaap:AccountsReceivableMember
us-gaap:CustomerConcentrationRiskMember
2024-01-01
2024-09-30
0001409197
2023-01-01
2023-12-31
0001409197
bspk:CustomerOneMember
us-gaap:AccountsReceivableMember
us-gaap:CustomerConcentrationRiskMember
2023-01-01
2023-12-31
0001409197
bspk:CustomerTwoMember
us-gaap:AccountsReceivableMember
us-gaap:CustomerConcentrationRiskMember
2023-01-01
2023-12-31
0001409197
us-gaap:WarrantMember
2024-01-01
2024-09-30
0001409197
us-gaap:StockOptionMember
2024-01-01
2024-09-30
0001409197
us-gaap:FurnitureAndFixturesMember
2024-09-30
0001409197
bspk:WonderLeafMember
2023-01-03
2023-01-03
0001409197
bspk:WonderLeafMember
2023-01-03
2023-01-03
0001409197
bspk:WonderLeafMember
2023-01-03
0001409197
bspk:WonderLeafMember
us-gaap:CommonStockMember
2024-01-01
2024-09-30
0001409197
bspk:WonderLeafMember
2024-01-01
2024-09-30
0001409197
us-gaap:FurnitureAndFixturesMember
2023-12-31
0001409197
us-gaap:MachineryAndEquipmentMember
2024-09-30
0001409197
us-gaap:MachineryAndEquipmentMember
2023-12-31
0001409197
us-gaap:PropertyPlantAndEquipmentOtherTypesMember
2024-09-30
0001409197
us-gaap:PropertyPlantAndEquipmentOtherTypesMember
2023-12-31
0001409197
bspk:MichaelFeinsodMember
2023-01-01
2023-12-31
0001409197
2023-09-05
0001409197
2023-09-05
2023-09-05
0001409197
bspk:NotePayableMember
2024-09-30
0001409197
bspk:InfinityManagementLLCMember
2024-01-01
2024-09-30
0001409197
bspk:InfinityManagementLLCMember
2023-01-01
2023-12-31
0001409197
bspk:UnsecuredNotePayableMember
2024-09-05
0001409197
us-gaap:WarrantMember
2024-02-16
2024-02-16
0001409197
us-gaap:WarrantMember
2024-02-16
0001409197
us-gaap:MeasurementInputExpectedDividendRateMember
2024-02-16
0001409197
us-gaap:MeasurementInputOptionVolatilityMember
2024-02-16
0001409197
us-gaap:MeasurementInputRiskFreeInterestRateMember
2024-02-16
0001409197
us-gaap:MeasurementInputExpectedTermMember
2024-02-16
0001409197
us-gaap:WarrantMember
2024-05-20
2024-05-20
0001409197
us-gaap:WarrantMember
2024-05-20
0001409197
us-gaap:MeasurementInputExpectedDividendRateMember
2024-05-20
0001409197
us-gaap:MeasurementInputOptionVolatilityMember
2024-05-20
0001409197
us-gaap:MeasurementInputRiskFreeInterestRateMember
2024-05-20
0001409197
us-gaap:MeasurementInputExpectedTermMember
2024-05-20
0001409197
us-gaap:WarrantMember
2024-06-06
2024-06-06
0001409197
us-gaap:WarrantMember
2024-06-06
0001409197
us-gaap:MeasurementInputExpectedDividendRateMember
2024-06-06
0001409197
us-gaap:MeasurementInputOptionVolatilityMember
2024-06-06
0001409197
us-gaap:MeasurementInputRiskFreeInterestRateMember
2024-06-06
0001409197
us-gaap:MeasurementInputExpectedTermMember
2024-06-06
0001409197
us-gaap:WarrantMember
2024-09-30
0001409197
bspk:WonderleafPurchaseAgreementMember
2024-09-30
0001409197
us-gaap:SeriesAPreferredStockMember
2024-06-30
0001409197
us-gaap:SeriesAPreferredStockMember
2023-06-30
0001409197
us-gaap:SeriesAPreferredStockMember
2024-09-30
0001409197
us-gaap:SeriesAPreferredStockMember
2023-09-30
0001409197
us-gaap:SeriesCPreferredStockMember
2023-09-30
0001409197
us-gaap:SeriesCPreferredStockMember
2024-01-01
2024-09-30
0001409197
bspk:TwentyTwentyOneEquityIncentivePlanMember
2021-12-14
2021-12-14
0001409197
2022-08-01
2022-08-01
0001409197
us-gaap:ShareBasedCompensationAwardTrancheOneMember
2022-08-01
2022-08-01
0001409197
us-gaap:ShareBasedCompensationAwardTrancheTwoMember
2022-08-01
2022-08-01
0001409197
2022-01-01
2022-12-31
0001409197
bspk:ConsultantsAndEmployeesMember
2024-08-31
2024-08-31
0001409197
bspk:ConsultantsAndEmployeesMember
2024-08-31
0001409197
us-gaap:WarrantMember
bspk:SeniorSecuredNoteMember
2024-02-16
0001409197
bspk:TwentyTwentyOneEquityIncentivePlanMember
bspk:MrGarthMember
2021-12-14
2021-12-14
0001409197
bspk:TwentyTwentyOneEquityIncentivePlanMember
bspk:MrGarthMember
2021-12-13
0001409197
bspk:TwentyTwentyOneEquityIncentivePlanMember
bspk:MrGarthMember
2024-01-01
2024-09-30
0001409197
bspk:MrGarthMember
2024-07-01
2024-09-30
0001409197
bspk:MrGarthMember
2024-01-01
2024-09-30
0001409197
bspk:MrGarthMember
2023-07-01
2023-09-30
0001409197
bspk:MrGarthMember
2023-01-01
2023-09-30
0001409197
bspk:MrFeinsodMember
2021-12-14
2021-12-14
0001409197
bspk:MrFeinsodMember
2021-12-13
0001409197
bspk:MrFeinsodMember
2024-01-01
2024-09-30
0001409197
bspk:MrFeinsodMember
2024-07-01
2024-09-30
0001409197
bspk:MrFeinsodMember
2023-07-01
2023-09-30
0001409197
bspk:MrFeinsodMember
2023-01-01
2023-09-30
0001409197
2023-08-17
0001409197
2023-08-17
2023-08-17
0001409197
us-gaap:EmployeeStockMember
2024-07-01
2024-09-30
0001409197
us-gaap:EmployeeStockMember
2024-01-01
2024-09-30
0001409197
us-gaap:EmployeeStockMember
2023-07-01
2023-09-30
0001409197
us-gaap:EmployeeStockMember
2023-01-01
2023-09-30
0001409197
2024-01-08
0001409197
bspk:VestMember
2024-01-08
2024-01-08
0001409197
bspk:VestMember
2024-01-15
2024-01-15
0001409197
2024-03-01
0001409197
us-gaap:RestrictedStockMember
bspk:TwentyTwentyOneEquityIncentivePlanMember
bspk:MrGarthMember
2024-03-01
0001409197
us-gaap:CommonStockMember
2024-03-01
2024-03-01
0001409197
bspk:MrGarthMember
us-gaap:CommonStockMember
2024-03-01
2024-03-01
0001409197
bspk:SeveralEmployeesOptionsMember
2024-07-01
2024-09-30
0001409197
bspk:SeveralEmployeesOptionsMember
2024-01-01
2024-09-30
0001409197
us-gaap:WarrantMember
2023-12-31
0001409197
us-gaap:WarrantMember
2023-12-31
2023-12-31
0001409197
us-gaap:WarrantMember
2024-01-01
2024-09-30
0001409197
2023-12-31
2023-12-31
0001409197
bspk:HunterGarthMember
2021-12-14
2021-12-14
0001409197
us-gaap:RestrictedStockMember
bspk:TwoThousandTwentyOneEquityIncentivePlanMember
bspk:MrGarthMember
2021-12-14
2021-12-14
0001409197
bspk:TwoThousandTwentyOneEquityIncentivePlanMember
bspk:MrGarthMember
2021-12-14
2021-12-14
0001409197
bspk:MrGarthMember
2021-12-14
2021-12-14
0001409197
bspk:MrGarthMember
2021-12-13
2021-12-13
0001409197
bspk:MichaelFeinsodMember
us-gaap:RestrictedStockMember
bspk:TwoThousandTwentyOneEquityIncentivePlanMember
2021-12-14
2021-12-14
0001409197
bspk:MrFeinsodMember
bspk:TwoThousandTwentyOneEquityIncentivePlanMember
2021-12-14
2021-12-14
0001409197
bspk:MrFeinsodMember
2021-12-14
2021-12-14
0001409197
bspk:MrFeinsodMember
2021-12-13
2021-12-13
0001409197
bspk:InfinityManagementLLCMember
2023-12-31
0001409197
bspk:InfinityManagementLLCMember
2024-09-30
0001409197
bspk:DebentureAgreementMember
2021-10-28
0001409197
2022-08-31
2022-08-31
0001409197
bspk:InventoryEarnOutMember
2022-08-31
2022-08-31
0001409197
2022-11-11
0001409197
bspk:MrGarthMember
2021-12-14
2021-12-14
0001409197
us-gaap:RestrictedStockMember
bspk:EquityIncentivePlanOneMember
bspk:MrGarthMember
2021-12-14
0001409197
bspk:EquityIncentivePlanOneMember
bspk:MrGarthMember
2021-12-14
2021-12-14
0001409197
us-gaap:StockOptionMember
bspk:EquityIncentivePlanOneMember
bspk:MrGarthMember
us-gaap:CommonStockMember
2021-12-14
0001409197
bspk:MrGarthMember
us-gaap:CommonStockMember
2021-12-13
2021-12-13
0001409197
bspk:MrFeinsodMember
2021-12-14
2021-12-14
0001409197
us-gaap:RestrictedStockMember
bspk:EquityIncentivePlanOneMember
bspk:MrFeinsodMember
2021-12-14
0001409197
bspk:EquityIncentivePlanOneMember
bspk:MrFeinsodMember
2021-12-14
2021-12-14
0001409197
us-gaap:StockOptionMember
bspk:EquityIncentivePlanOneMember
bspk:MrFeinsodMember
us-gaap:CommonStockMember
2021-12-14
0001409197
bspk:MrFeinsodMember
us-gaap:CommonStockMember
2021-12-13
2021-12-13
0001409197
bspk:OsirisLLCMember
2022-08-11
2022-08-11
xbrli:shares
iso4217:USD
iso4217:USD
xbrli:shares
xbrli:pure
In connection with the Quarterly Report on Form
10-Q of Bespoke Extracts, Inc., as filed with the U.S. Securities and Exchange Commission on the date hereof (the “Report”),
I, Michael Feinsod, the Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec.
906 of the Sarbanes-Oxley Act of 2002, that: